OCULAR ASSESSMENT OF PATIENTS TREATED WITH TAMOXIFEN

Abstract

Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in 4 patients receiving high-dose tamoxifen therapy for > 1 yr. Patients (19) treated with tamoxifen for periods of 3 mo. to 4 yr at normal dose levels were studied and no ocular changes attributable to the drug were observed.